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Abstract
Aims/hypothesis Foot ulcers in people with diabetes are a
common and serious global health issue. Dressings form a
key part of ulcer treatment. Existing systematic reviews are
limited by the lack of head-to-head comparisons of alternative
dressings in a field where there are several different dressing
options. We aimed to determine the relative effects of alterna-
tive wound dressings on the healing of diabetic foot ulcers.
Methods This study was a systematic review involving
Bayesian mixed treatment comparison. We included rando-
mised controlled trials evaluating the effects on diabetic foot
ulcer healing of one or more wound dressings. There were
no restrictions based on language or publication status.
Results Fifteen eligible studies, evaluating nine dressing
types, were included. Ten direct treatment comparisons were
made. Whilst there was increased healing associated with
hydrogel and foam dressings compared with basic wound
contactmaterials,thesefindingswerebasedondatafromsmall
studies at unclear or high risk of bias. The mixed treatment
comparisonsuggested that hydrocolloid-matrix dressingswere
associated with higher odds of ulcer healing than all other
dressing types; there was a high degree of uncertainty around
these estimates, which were deemed to be of very low quality.
Conclusions/interpretation These findings summarise all
available trial evidence regarding the use of dressings to
heal diabetic foot ulcers. More expensive dressings may
offer no advantages in terms of healing than cheaper basic
dressings. In addition, evidence pointing to a difference in
favour of ‘advanced’ dressing types over basic wound con-
tact materials is of low or very low quality.
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Abbreviations
BNF British National Formulary
CrI Credible interval
DIC Deviance information criterion
GRADE Grading of Recommendations Assessment,
Development and Evaluation
MTC Mixed treatment comparison
NHS UK National Health Service
PRISMA Preferred Reporting Items for Systematic
Reviews and Meta-Analyses
RCT Randomised controlled trial
SUCRA Surface under the cumulative ranking
Background
Foot ulcers in people with diabetes are a common, serious
and costly global health issue [1]. In 2007, the mean total
reimbursement cost for a US Medicare patient with a
Electronic supplementary material The online version of this article
(doi:10.1007/s00125-012-2558-5) contains peer-reviewed but unedited
supplementary material, which is available to authorised users.
J. C. Dumville (*):S. O’Meara
Department of Health Sciences,
University of York, Area 2, Seebohm Rowntree Building,
York YO10 5DD, UK
e-mail: jo.dumville@york.ac.uk
M. O. Soares
Centre for Health Economics, University of York,
York, UK
N. Cullum
School of Nursing, Midwifery and Social Work,
University of Manchester,
Manchester, UK
Diabetologia (2012) 55:1902–1910
DOI 10.1007/s00125-012-2558-5
# The Author(s) 2012. This article is published with open access at Springerlink.comdiabetic foot ulcer was $33,000 (for all Medicare services)
[2]. Dressings form a key part of ulcer treatment, with
clinicians having many different types to choose from. Ar-
guably, wound dressings are perceived as cheap and ‘inert’
items, thus consideration of their use in relation to existing
evidence receives limited attention. However, as dressing
types grow in number and complexity, and with claims of
promoting healing, expenditure also increases. Drugs and
devices prescribed in the UK National Health Service
(NHS) are listed in the British National Formulary (BNF)
[3] and the costs of non-hospital prescriptions in England
are recorded by the NHS. Of the 201 BNF categories in
2010, the community prescription cost of the ‘wound man-
agement and other dressings’ section was £136 million [4],
making it the 17th most costly section (the most costly
section is ‘drugs for diabetes’ at over £700 million).
Dressings are widely used in wound care, with the aim of
protecting and managing the wound and promoting healing.
Several dressing types are available to treat complex
wounds such as diabetic foot ulcers. We present a brief
overview of dressing options using BNF-derived categories
(electronic supplementary material [ESM] Table 1). Current
guidelines for the treatment of diabetic foot ulcers maintain
that clinical judgement should be used to select a moist
wound dressing [5].
Nurses and podiatrists with whom we collaborate
requested a review of current evidence regarding the use
of dressings to heal diabetic foot ulcers in order to address
treatment uncertainty in this area. Two recent systematic
reviews have assessed the use of dressings to treat diabetic
foot ulcers (literature searched to 2006 in the first and from
2006 to 2010 in the second) [6, 7] with the results of each
search presented as a separate report with simple narrative
review. The authors concluded that there was no evidence
that any one dressing type was superior to another in terms
of promoting ulcer healing. A further Cochrane systematic
review that assessed the debridement of diabetic foot ulcers
(literature searched to June 2009) found that significantly
more hydrogel-treated ulcers healed compared with those
treated with gauze or standard care (risk ratio 1.84 [95% CI
1.30, 2.61]) [8]. This estimate is based on three, poorly
reported trials (follow-up period: 3 to 5 months) involving
198 participants.
To date, all previous reviews are limited by the lack of
direct, head-to-head comparisons of alternative dressings in
a field in which there are many dressing options. Thus, we
aimed to evaluate the effects of alternative wound dressings
on the healing of foot ulcers in people with diabetes by
synthesising all available randomised controlled trial
(RCT) evidence. As well as employing standard meta-
analytical techniques for head-to-head comparisons we con-
ducted a mixed treatment comparison (MTC) [9, 10], which
allows consideration of both direct and indirect evidence to
inform relative effectiveness estimates. These analyses were
conducted from a Bayesian perspective; an alternative to the
standard frequentist approach [11].
Furthermore, while there is growing interest in the con-
duct of MTC and the value of resulting data for clinical
decision making, there is currently no established method of
appraising and presenting the quality of MTC estimates.
Quality assessment tools such as Grading of Recommenda-
tions Assessment, Development and Evaluation (GRADE)
are available for standard pair-wise meta-analysis [12];
GRADE assesses the quality of estimates by evaluating:
(1) the component studies; (2) how results compare across
the different studies; and (3) the magnitude of the treatment
effects from the synthesis. Such consideration is crucial in
facilitating interpretation of results for clinical practice or
policy. Without an equivalent process for MTC there is a
risk that such estimates are used to inform decision making
without due consideration of quality. We aimed to undertake
a preliminary MTC quality assessment process in this study.
Methods
Study selection
This review was based on a pre-specified protocol [13]. We
planned to include published or unpublished reports of
RCTs, in any language and conducted in any country or
setting, that evaluated the effects of wound dressings on the
healing of diabetic foot ulcers. We accepted study authors’
definitions of what constituted a diabetic foot ulcer and
included trials that recruited patients with any type of dia-
betic foot ulcer. There was no restriction in relation to
participant age. We included any RCT in which the dressing
type was the only systematic difference between treatment
groups. Trials of non-dressing topical treatments (e.g.
lotions, growth factors and skin replacements) were excluded
as these were considered to be beyond the remit of this
evidence synthesis; however trials of impregnated dressings
and saline-moistened dressings (e.g. gauze) were eligible for
inclusion. We also excluded trials that compared different
brands of the same dressing type.
Our primary outcome was ulcer healing, measured using
time to healing and/or number of ulcers completely healed
within a specific time period (we assumed this period to be
the trial follow-up time unless otherwise stated).
Data sources and searches
The search string for CENTRAL (ESM text, section 1) was
adapted for use in other databases, all being searched from
inception to June 2011: Cochrane Wounds Group Specialised
Register, Ovid MEDLINE, Ovid EMBASE and EBSCO
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the Cochrane Highly Sensitive Search Strategy for identifying
randomised trials in MEDLINE: sensitivity- and precision-
maximising version (2008 revision) [14]. The EMBASE and
CINAHL searches were combined with the trial filters devel-
oped by the Scottish Intercollegiate Guidelines Network [15].
Reference lists of included studies and previous systematic
reviews were also searched. We contacted appropriate manu-
facturing companies for details of any unpublished studies.
Two review authors independently assessed the titles and
abstracts of retrieved studies for relevance. After this initial
assessment, we obtained all studies felt to be potentially
relevant in full. We attempted to contact researchers to obtain
any required additional information not contained in the trial
reports.
Data extraction
Details of the eligible studies were extracted and summarised
usingastandardiseddataextractionsheet.Tworeviewauthors
extracted data independently with disagreements resolved by
discussion. If data were missing from reports, attempts were
made to contact the study authors to obtain further informa-
tion. Studies published in duplicate were included once but a
comprehensive dataset was compiled from all publications.
Risk of bias assessment (individual studies) Two review
authors independently assessed each individual included
study using the Cochrane Collaboration tool for assessing
risk of bias, which addresses six specific domains [16].
Disagreements about risk of bias assessment were resolved
by discussion and trial authors contacted where possible
when data were missing. We classified trials as being at
high risk of bias if they were rated 'No' for any of three
key criteria (randomisation sequence, allocation concealment,
and blinded outcome assessment).
Data synthesis and analysis
A brief primer on this subject can be found in section 2 of
the ESM text.
Relative treatment effects on ulcer healing:statistical analysis
Direct data Where head-to-head (direct) treatment compar-
isons were reported in one trial only, ORs and 95% CIs were
calculated. Where direct comparisons of dressings were
available from more than one trial, appropriate standard
meta-analyses (using ORs) were undertaken using Winbugs
(available at www.mrc-bsu.cam.ac.uk/bugs). Results were
reported with 95% credible intervals (CrIs)—the Bayesian
equivalent of CIs, reflecting the uncertainty surrounding
estimates. Unlike 95% CIs, 95% CrIs can be interpreted
as: the (posterior) probability that these limits contain the
parameter mean is 95%. Fixed and random effects models
were considered and model fit assessed using the posterior
mean of the residual deviance and the deviance information
criterion (DIC).
Quality assessment of evidence generated using direct
data The overall quality of evidence surrounding estimates
of effect using direct evidence only was assessed using
GRADE [12]. GRADE assessment focuses not on individual
studies but on a body of evidence and considers issues wider
than threats to interval validity, including imprecision, incon-
sistency, indirectness and publication bias. Problems in any
category lead to the quality of the evidence being decreased
(we did not consider increasing the quality of evidence
options). In reflecting the quality of an estimate drawn from
multiple sources, GRADE aims to help the reader consider
h o wc o n f i d e n tw ea r et h a ta ne f f e c te s t i m a t ei sc o r r e c t[ 12].
Quality of evidence can be rated as high, moderate, low or
very low.
Direct and indirect data: MTC
To maximise the use of all available trial data and to facil-
itate decision making regarding dressing choice we con-
ducted an MTC [9, 10]. This approach links head-to-head
comparison data from trials, via common comparators, into
a network that can then be used to calculate indirect esti-
mates of relative treatment effect. In a simple example
where there are three treatments A, B and C compared in
two head-to-head trials, A vs B and B vs C, as B is a
common comparator the network A–B–C can be formed.
These data can then be used to obtain an indirect estimate of
the relative effects of A vs C. The MTC used OR as the
measure of effectiveness and was conducted from a Bayesian
perspective, again using Winbugs. Fixed and random effects
models were fitted to these data with model fit assessed using
residual deviance and DIC as before.
The treatment with the highest OR estimate in the MTC
is expected to have the highest likelihood of healing diabetic
foot ulcers. However, it is important to fully comprehend the
uncertainty around such estimates. In addition to presenting
CrIs, we represented uncertainty regarding treatment choice
as the probability that each dressing was the ‘best’ treatment
in terms of being the most likely to heal diabetic foot ulcers
(when compared with all other evaluated treatments). To
provide a complete overview of the spread of decision
uncertainty around the choice of a ‘best’ treatment we then
presented the probability of each treatment being the second
best treatment and the third best and so on. Alternatively,
this can be conceptualised, for each treatment, as a cumula-
tive probability at each rank, summarised numerically as a
surface under the cumulative ranking (SUCRA) for each
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a treatment was certain to be the best and 0 (0%) when a
treatment was certain to be the worst.
Inconsistencies When direct and indirect evidence exists
(i.e. a loop of evidence in the network diagram), inconsis-
tencies between the ORs and intervals of these two sources
may arise. We formally assessed for inconsistencies using
the back calculation method suggested by Bucher et al [18,
19]. Briefly, where direct and indirect values could be com-
pared, these values were calculated for each treatment, com-
pared statistically against a null hypothesis that there would
be no difference between them, and the p value for this test
presented. We also extended the analysis to include an
inconsistency model, which omitted consistency equations.
Finally, potential inconsistencies between our direct and
MTC estimates were also assessed by qualitatively compar-
ing estimates of standard meta-analysis (direct) and MTC
(direct and indirect). See section 3 of the ESM text for more
information on inconsistencies.
Sensitivity analysis We evaluated the sensitivity of the net-
work to individual trials; where links were informed by
more than one trial, we removed each trial one at a time
(giving n−1 for each analysis) and investigated the impact
on the probability of which treatment was ‘best’.
Quality assessment of evidence generated from the
MTC We were also keen to reflect the quality of the evi-
dence provided by the MTC so that this quality is transpar-
ently reflected in the strength of the conclusions made, as
would be expected in other forms of evidence synthesis;
however there is no established method for doing this in
MTCs. We therefore modified the GRADE approach (we
called this iGRADE) to allow us to access and communicate
the quality of this MTC-derived evidence. We worked with
the five categories in GRADE that allow the quality of
evidence to be decreased; however we altered the focus of
some categories so they were relevant for assessing an MTC
(see ESM Table 2 for a full description of the iGRADE
tool). No formal down-weighting of evidence was undertaken
based on this assessment.
Results
Study characteristics
A Preferred Reporting Items for Systematic Reviews and
Meta-Analyses (PRISMA) flowchart is presented in Fig. 1
(a summary of study characteristics for the 15 included
studies is presented in ESM Table 3). All 15 included
studies [20–34] reported the number of ulcers healed, while
only three [21, 23, 25] reported median time to healing.
Thus we focused our analyses on the proportion of ulcers
healed. In terms of ulcer severity, four studies reported
inclusion of Wagner grades 1 or 2 ulcers [22, 27, 28, 32]
and one study specified that ulcers were superficial [23]. A
further three studies specified that ulcers involving tendons,
joint spaces and/or bone were excluded. Only one study
specifically included more severe grade 3 and 4 ulcers
[34]. Eight studies clearly excluded those with arterial dis-
ease [21, 23, 24, 26, 28, 30–32]. Eight studies excluded
participants that had infected or sloughy ulcers [21, 23–27,
30, 32]. Only one study [33], comparing a basic contact
wound with a hydrogel dressing, clearly specified the inclu-
sion of people with necrotic and infected wounds. The
evidence base therefore overwhelmingly relates to people
with less severe and less complex diabetic foot ulceration.
In terms of risk of bias, four included studies were
deemed to be at high risk of bias [20, 23, 24, 33]. Only
one study [26] was deemed at low risk of bias. The remain-
ing ten studies were rated unclear for one or more key
domains and hence we could not confidently judge their
risk of bias (the outcome of the risk of bias assessment is
summarised in ESM Table 3).
Relative treatment effects on ulcer healing
Direct data
A summary of the network of dressing trials that measured
healing in participants with diabetic foot ulcers is illustrated
in Fig. 2. Ten direct treatment comparisons were made in the
346 unique citations retrieved 
and screened for potential 
inclusion 
103 full reports (for 85) 
studies) screened for 
inclusion  
The study was not randomised (n=9);
No homogenous dressing group was 
evaluated (n=16); 
Another intervention, not a dressing, 
differed between study groups (n=25); 
A relevant outcome was not reported or 
not reported for diabetic foot ulcers (n=9);
Other (n=11)
15 studies included
Fig. 1 PRISMA overview of study identification and selection process
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more than one trial where standard meta-analysis could be
conducted (all fixed effect). The overall quality of evidence
for each direct link was assessed using the GRADE quality
of evidence scale (Table 1): four links were formed by low
quality evidence and six by moderate quality evidence. It is
important to note that three of these four links were informed
by the same three-arm trial assessed as being at low risk of
bias.
There was evidence that hydrogel dressings were associ-
ated with significantly higher odds of ulcer healing than
basic wound contact dressings (OR 3.10 [95% CI 1.51,
5.50]) (Table 1). However, this finding was driven by low
quality evidence, encompassing two small studies (sample
Basic wound contact
Alginate
Foam 
Hydrocolloid 
(fibrous)
Iodine-
impregnated
Hydrogel 
Silver hydrocolloid 
(fibrous)
Protease-
modulating 
Hydrocolloid-matrix  n=2
n=3
n=2 
n=1 
n=1 
n=1 
n=3
n=1
n=2
n=1
Fig. 2 A network summary of
all comparisons informed by
direct trial data for wound
dressings for diabetic foot
ulcer healing. The lines link
dressings that have been
compared (in the treatment of
diabetic foot ulcers) using a
randomised controlled trial.
(n=x) refers to the number of
trials making this comparison.
One three-arm trial was includ-
ed that randomised to hydro-
colloid (fibrous), iodine-
impregnated and basic wound
contact
Table 1 Results from direct and MTC analysis with assessment of overall quality of evidence using the GRADE (direct) and iGRADE (MTC)
quality of evidence scales
The treatment on the horizontal axis is always the reference treatment
Direct data are presented as ORs and 95% CrIs for meta-analysed data (indicated by
a) and ORs and 95% CIs for non-pooled data (i.e. one trial). All
MTC data are presented as ORs and 95% CrIs
In each cell, the left-hand value is the result of standard meta-analysis (using direct/head-to-head data only). The right-hand value is the MTC estimate
(direct and/or indirect evidence).The shaded circles illustrate the assessed quality of evidence of estimates. Purple equates to very low quality evidence
(VL); red equates to low evidence (L); yellow equates to moderate evidence (M) and green to high quality (H, none reported)
aMeta-analysed data
bComparisons where credibility intervals do not cross 1
cThree-arm trial
Grey-shaded areas denote reverse odds ratios to those presented (with dressings in column as reference), which were not calculated
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risk of bias and one at high risk of bias. Foam dressings
were also associated with higher odds of ulcer healing
compared with basic wound contract dressings (OR 4.01
[95% CI 1.07, 10.7]) (Table 1); again the estimate was
considered to be of low quality. In the remaining five single
study comparisons there was no evidence of any difference
between one dressing and another. In general, estimates had
large uncertainty due to low sample sizes.
MTC data
Based on assessment of fit, a fixed effect model was
employed; there was minimal difference in mean residual
deviances and DIC between the different models tested
(fixed effect, simple random effects and full random effects,
which accounted for correlation within the three-arm trial),
thus the least complex model, given the limited data available
for analysis, was applied.
There was a high degree of uncertainty in the many links
in the network, especially those that were not informed by
direct data (Table 1). Evidence remained that both foam and
hydrogel dressings were expected to be associated with
higher odds of ulcer healing than basic wound contact
dressings, although uncertainty was high (Table 1). These
dressings were estimated to be more effective than fibrous
hydrocolloid and iodine-impregnated dressings, these results
being driven by the more certain finding from a large, three-
arm,trial thatthere was nodifference inulcer healing between
fibrous hydrocolloid dressings and basic wound contract
dressings and iodine-impregnated dressings and basic wound
contact dressings. In this situation we must consider the qual-
ity of the evidence provided in these analyses (results of
iGRADE analysis are presented in Table 1). In general, the
network included several small studies leading to high impre-
cision; in addition, estimates were informed by studies with
high risk of bias. We stress that the research deriving the
estimates for fibrous hydrocolloid and iodine-impregnated
dressings is regarded as being of higher quality, whereas
evidence on hydrogel and foam dressings is classed as having
more limited quality (Table 1)[ 22, 27, 29, 31, 33, 34].
A valuable feature of Bayesian methods is the ability to
illustrate the impact of uncertainty on decision making by
assessing theprobability thateachdressingtreatmentincluded
in the network is the best in terms of ulcer healing. Notably,
the treatment associated with the greatest probability of heal-
ing was hydrocolloid-matrix (70%, Table 2). This result
reflects the high relative effect estimates generated by the
MTC from available indirect evidence (OR 10.38 [95% CrI
1.19, 42.1], Table 1): hydrocolloid-matrix had higher odds of
healing than foam and foam had higher odds of healing than
basic wound contact. Again, interpretation of the evidence
must also consider its quality; these results are drawn from
low qualityevidenceand thislimitsthe confidencewehavein
these conclusions. Estimates for the three dressings with the
highest probability of being the best (hydrocolloid-matrix,
hydrogel and foam) are informed by low quality evidence,
while estimates for some dressings with 0% probability of
being the best are informed by moderate quality evidence.
SUCRA estimates reflect these findings considered cumula-
tively across the ranks 1–9: hydrocolloid-matrix dressings
have a SUCRA of 92%, foam dressings 83% and hydrogel
78%, while basic wound contact has a SUCRA of 11%
(Table 2), where a SUCRA of 100% means a treatment is
certain to be the best and a treatment with a SUCRA of 0% is
certain to be the worst.
Inconsistencies
There was one data loop where both direct and indirect data
informed relative treatment effectiveness estimates; the pos-
sibility of inconsistency was investigated (ESM Fig. 1).
While there was no evidence of statistically significant dis-
crepancies between the direct and the indirect data, given
the uncertainty in the data only very large differences were
likely to result in statistical significance. Qualitative assess-
ment was also undertaken (ESM text, section 4), which also
concluded that there was no evidence of inconsistencies
between direct and indirect data.
Sensitivity analysis
The sensitivity of the network to specific studies was also
investigated. In total, 11 analyses with 14 (rather than the
total 15) included studies were performed and the probability
of each dressing being the best was assessed. Basic wound
contact layer, alginate, fibrous hydrocolloid, impregnated-
iodine, and silver fibrous hydrocolloid dressings continued
to have very low, or no probability of being the ‘best’ treat-
ment in any sensitivity analysis. Hydrocolloid-matrix
remained the most likely ‘best’ treatment in ten of the 11
analyses (probability of being ‘best’ ranging from 62% to
75%; ESM Table 4). The exception was when the largest
study comparing hydrogel with a basic wound contact dress-
ing was removed [34]. This resulted in the direct odds of
healing with hydrogel (and the uncertainty around this esti-
mate) increasing dramatically since the two remaining small
trials both significantly favoured hydrogel with hydrogel
having the highest probability of healing (62%, with
hydrocolloid-matrix at 35%).
Discussion
Currently, the findings from good quality research provide no
evidence to suggest that fibrous hydrocolloid (hydrofibre),
Diabetologia (2012) 55:1902–1910 1907iodine-impregnated and protease-modulating dressings are
more effective than basic wound contact materials in terms
of ulcer healing. Thus, in the generally non-complex wounds
studied, there was no evidence of a difference in healing
between more expensive dressings compared with cheaper
alternatives, nor between antimicrobial/antiseptic dressings
and non-antimicrobial/antiseptic dressings.
Conversely, evidence pointing to a difference in favour of
‘advanced’ dressing types over basic wound contact materi-
als is of low or very low quality. Thus for dressings such as
hydrocolloid-matrix, we can only conclude that there is no
high quality evidence to suggest that this dressing type is
more effective than any other, or alternatively that any
evidence suggesting that hydrocolloid-matrix dressings are
more effective in healing diabetic foot ulcers is at high risk
of bias.
Strengths and limitations
The findings presented result from analysis of the most com-
prehensive evidence base available from across the world
regarding the effect on healing of dressings to treat diabetic
foot ulcers. While some may argue that the presence of sparse
data should preclude any statistical synthesis of the evidence,
we counter that clinicians cannot postpone treatment selection
until high quality evidence has accumulated. Furthermore,
comprehensive evidence synthesis highlights to researchers
and clinicians the state of the current evidence base and its
limitations as well as signposting where future research might
focus. A further strength of this study is the application of an
exploratoryframeworkbasedonGRADEtoundertakequality
assessment of MTC estimates and the presentation offindings
in light of this assessment.
We do acknowledge that there are limitations in synthesis-
ing sparse data, particularly in preventing further exploration
of the potential impact of heterogeneity, for example length of
trial follow-up. However, it is important to note that this is an
issue for several evidence synthesis projects in wound care
where data are sparse and follow-up times vary. In other net-
works, this has been dealt with by assuming a constant hazard
of healing over time—although this assumption is potentially
also not valid. In general, the limited evidence base prevented
the application of a random effects model, however, we
acknowledge that in other situations this type of model may
be more appropriate than a fixed effects approach.
Quality assessment of MTC estimates
We have developed and employed a preliminary framework
for quality assessment of MTC evidence based on GRADE.
In this example, we aimed to assess the feasibility and
highlight potential challenges of applying quality assess-
ment to MTC evidence. We note, however, that our modi-
fied approach has not been validated and is not recognised
by GRADE.
It may be that other tools, rather than GRADE, would
provide a better starting point for assessing the quality of
MTC outputs. For example, GRADE’s remit extends to
guiding clinical- and policy-level decision making, which
are less relevant to MTC assessment. At the very least
within our modified approach there are still several areas
that need addressing, emphasising future challenges in de-
veloping such a scale: for example indirectness as a charac-
teristic of the evidence is not easy to apply to MTC (as
indirect data is a common feature that should not necessarily
result in downgrading) and is perhaps more appropriately
referred to as ‘inconsistency’ in this context. However, in
standard GRADE, the term ‘inconsistency’ relates to unex-
plained heterogeneity. Within iGRADE we considered un-
explained heterogeneity and inconsistency (the MTC-
related meaning) together in one category. We then added
a separate category that assessed the impact of sensitivity
Table 2 Treatment rankings
Table 2 shows the probability that each treatment is the best in terms of healing diabetic foot ulcers, then the second best in terms of healing diabetic
foot ulcers and so on. The shaded square highlights the treatment with the highest probability in each column.
aMust be interpreted with caution owing to the risk of bias in the research
1908 Diabetologia (2012) 55:1902–1910analysis on results. Our aim here was to assess the stability
of the network and thus its estimates. Finally, imprecision
could perhaps be omitted from this tool as it may be more
useful for the reader to use their own judgement regarding
the width of CrIs and what they mean. Quality assessment of
MTC output is a complex area and further research is
required; however, we emphasise that, currently, this work
is the only example of formal quality assessment of MTC
outputs.
Conclusion and future research
These findings comprehensively summarise all trial evi-
dence available to decision makers regarding the use of
dressings to heal diabetic foot ulcers. This highlights that
more expensive dressings may offer no advantages in terms
of healing than cheaper, basic dressings. The work also
highlights the risk of bias in some studies and how this
can impact on interpretation of MTC findings.
The work provides a platform from which to consider
future research. Given the large number of dressing options
available to clinicians (while nine dressings have been evalu-
ated here there are many more for which no RCT data exist),
the design of any future studies should be driven by those
questions regarded as high priority by decision makers and
patients, and potentially guided by the data presented here.
Finally, the analysis conducted here highlights that concerted
efforts should be made in wound care, as in other fields, to
utilise health professional and participant time only in the
production of useful and valid research data.
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